AI assistant
Novartis AG — Director's Dealing 2018
Aug 8, 2018
940_dirs_2018-08-08_2d6b9cae-35f8-40c5-b67c-f4d09c369715.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AILERON THERAPEUTICS INC (ALRN)
CIK: 0001420565
Period of Report: 2018-08-06
Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-08-06 | Common Stock | S | 2942 | $3.02 | Disposed | 2450902 | Direct |
| 2018-08-07 | Common Stock | S | 1739 | $2.97 | Disposed | 2449163 | Direct |
Footnotes
F1: Reflects sales of common stock executed in multiple transactions at prices ranging from $3.00 to $3.03. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
F2: The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.
F3: Reflects sales of common stock executed in multiple transactions at prices ranging from $2.95 to $2.98. The price reported reflects the weighted average sale price. The Reporting Persons hereby undertake to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.